Validity of dual tracer 99mTc-tetrofosmin and 99mTc-pertechnetate subtraction parathyroid scintigraphy in patients with primary and secondary hyperparathyroidism
Background/Aim. Primary hyperparathyroidism (pHPT) is an endocrine disease with the third highest incidence of all endocrine disorders after diabetes mellitus and hyperthyroidism. pHPT is typically caused by a solitary parathyroid adenoma, less frequently by multiple parathyroid gland disease (MGD)...
Main Authors: | Dugonjić Sanja, Ajdinović Boris, Cerović Snežana, Janković Zoran |
---|---|
Format: | Article |
Language: | English |
Published: |
Military Health Department, Ministry of Defance, Serbia
2009-01-01
|
Series: | Vojnosanitetski Pregled |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0042-8450/2009/0042-84500912949D.pdf |
Similar Items
-
Estimation of 99mTc-ciprofloxacin accumulation indexes in bone and joint bacterial infections
by: Pucar Dragan, et al.
Published: (2009-01-01) -
Dual Tracer 99mTc-pertechnetate/99mTc-MIBI Dual-Time-Point SPECT/CT Parathyroid Gland Assessment Regarding to Parathyroid Gland Size and Biochemical Parameters – Two Years Single Imaging Centre Experience
by: Eva Krčálová, et al.
Published: (2019-04-01) -
Utility of 99mTc-Sestamibi SPECT/CT in the Early Localization of Metastatic Parathyroid Carcinoma
by: Patrick Earl Fernando, et al.
Published: (2018-06-01) -
The role of 18F-FCH PET/CT in patients with uremic hyperparathyroidism compared with 99mTc-sestaMIBI SPECT/CT and ultrasonography
by: Yu Xue, et al.
Published: (2019-12-01) -
Ultrastructure of hyperfunctioning parathyroid glands: Does it explain various patterns of 99mTc-sestamibi uptake
by: Abdelhamid H Elgazzar, et al.
Published: (2017-01-01)